论文部分内容阅读
目的:观察弗隆和氨鲁米特治疗绝经后晚期乳腺癌的疗效和不良反应。方法:50例绝经后晚期乳腺癌患者随机进入弗隆组26例和氨鲁米特组24例。弗隆2.5mg口服,每天1次。氨鲁米特,第1周125mg口服,每日2次;第2周,250mg,每日2次;第3周250mg,每日3次;从第4周开始,250mg,每日4次。治疗30天为1周期。结果:弗隆组有效患者(CR+PR)7例(26.9%),高于氨鲁米特组3例(12.5%),但差异无显著性(P=0.294)。两组病情稳定(SD)患者分别有14例(53.8%)和12例(50.0%);病情进展(PD)患者分别有5例(19.2%)和9例(37.5%)。两药疗效在不同受体状态、无病间期、病变部位和治疗阶段的分层比较,差异均无显著性(P值均>0.05)。弗隆组主要的不良反应有乏力(15.4%)、食欲下降(11.5%),头晕、恶心、头痛、嗜睡发生率均<8%,且程度较轻;氨鲁米特组恶心(25.0%)、呕吐(16.7%)发生明显高于弗隆组,差异有显著性P值分别为0.045和0.046,头晕(25.0%)、乏力(20.8%)、食欲下降(16.7%)、嗜睡(12.5%)、皮肤瘙痒(12.5%)的发生也均高于弗隆组,但差异无显著性(P值均>0.05),另外有1例患者出现过敏性皮疹。结论:弗隆治疗绝经后晚期乳腺癌有一定疗效,部分不良反应比氨鲁米特轻,患者耐受性强。
OBJECTIVE: To observe the efficacy and side effects of furundol and aminoglutethimide in the treatment of advanced postmenopausal women with breast cancer. Methods: Fifty patients with postmenopausal advanced breast cancer randomly entered 26 patients in Furong group and 24 patients in Aminomide group. Furong 2.5mg orally, 1 day. Ammonium Rumitum, 125 mg orally daily for 1 week, 2 times daily; 250 mg twice daily for 2 weeks; 250 mg 3 mg daily for 3 weeks; 250 mg daily for 4 weeks. Treatment for 30 days for a cycle. Results: 7 patients (26.9%) in the furosemide group (CR + PR) were higher than those in the aminoglutrimide group (12.5%), but the difference was not significant (P = 0.294). There were 14 cases (53.8%) and 12 cases (50.0%) in stable condition (SD) and 5 cases (19.2%) and 9 cases (37.5%) in condition progression (PD) respectively. The efficacy of the two drugs in different receptor status, disease-free interval, lesion site and treatment stage stratification comparison, the difference was not significant (P> 0.05). The main side effects of furundan were fatigue (15.4%), loss of appetite (11.5%), dizziness, nausea, headache and drowsiness <8% , Vomiting (16.7%) was significantly higher than furosemide group, the difference was significant P values were 0.045 and 0.046, dizziness (25.0%), fatigue (20.8%), loss of appetite (16.7%), lethargy , Pruritus (12.5%) were also higher than furosemide group, but the difference was not significant (P> 0.05). In addition, 1 patient had an allergic skin rash. Conclusion: Furong treatment of advanced postmenopausal breast cancer have a certain effect, part of the adverse reactions than ammonia luminosity is light, patients with strong tolerance.